Visual pathway disorders
Conditions
Interventions
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 100 Years
Inclusion criteria
Inclusion criteria: 1) ON patients with a diagnosis of optic neuromyelitis optica spectrum disease (NMOSD), multiple sclerosis (MS), or myelinating oligodendrocyte glycoprotein antibody-associated disease (MOGAD); 2) patients with AMD who were diagnosed for early, late wet (or not PCV), and late GA-type AMD, all graded as greater than or equal to 3 with reference to the Age-Related Eye Disease Study (AREDS) classification system (1999); (3) both eyes graded less than 3 by AREDS AMD grading can be enrolled in the ocular healthy control group; (4) Voluntarily sign a written informed consent form and be willing and able to undergo follow-up examinations for at least 3 years as specified in the protocol.
Exclusion criteria
Exclusion criteria: 1) Retinal or other ocular surgical procedures (other than cataract extraction) that have the potential to interfere with the assessment of the progression of visual loss; 2) Subjects with a history of disorders such as dementia or other serious illnesses that would interfere with cognitive functioning; 3) A diagnosis of depression or other Axis I disorder (including depression, anxiety, bipolar disorder or manic depression, hyperactivity, & schizophrenia) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision (DSM-IV), and current treatment for depression and cognitive disorders, among others; 4) Long-term need for any systemic or ocular medication with known retinal or optic nerve toxicity; 5) Intraocular pressure of 26mmhg or more or diagnosed with other eye diseases including glaucoma, diabetic retinopathy, uveitis, and endophthalmitis; 6) Cataract surgery within 3 months; 7) Other exclusion criteria include: any systemic disease with a poor five-year survival prognosis; any condition where poor adherence to follow-up is likely to occur; current participation in other studies that may affect the follow-up schedule of this study; use of systemic anti-angiogenic therapies to treat choroidal neovascularization or cancer; 8) Any other condition that, in the judgment of the investigator, makes enrollment in the study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MMSE score; | — |
Secondary
| Measure | Time frame |
|---|---|
| MRI;OCT; | — |
Countries
China
Contacts
Public ContactSun Xiaodong
Shanghai General Hospital
Outcome results
None listed